Lipitor Patent Protection

Health Blog : Patent Office: No Do-Over on Lipitor Patent

Lipitor has been one of the most effective and expensive drugs in recent memory. Using the patent protection to preserve the edge is both smart and legal.

Pfizer Gets Mixed Verdict in British Lipitor Patent Case - New

If the American case were to be decided in the same way as the British one, Pfizer could lose its patent protection for Lipitor in this country about a year.

FOXNews.com - Pfizer Wins Key Lipitor Patent Case - Business And

Pfizer Wins Key Lipitor Patent Case, A federal judge Friday upheld the validity Pfizer will now have patent protection on the world's best-selling drug.

Pfizer's atorvastatin (Lipitor) patent safe

Of the main patent covering atorvastatin, the active ingredient in Lipitor, maintaining patent protection for Lipitor in the US until March 2010.

Patents on Merck's Zocor and Pfizer's Zoloft about to expire - Jun

Zocor losing patent protection. Merck and Pfizer stand to lose billions in sales as two Zocor's patent loss may also threaten sales of Pfizer's Lipitor.

Patent Baristas » Pfizer To Get Re-Examination Certificate on

The ‘156 patent at issue with the current re-exam is set to expire in 2017, the useful patent protection of the drug (keep in mind that Lipitor is set.

Verdict mixed in Lipitor patent fight | The San Diego Union-Tribune

Next year, two other cholesterol-lowering drugs lose patent protection, and there is concern that Lipitor sales growth may sputter as managed-care companies.

U.S. To Uphold Pfizer's Lipitor Patent - Pharma & Bio Ingredients

"We see this decision as affirming that important advances in medical innovation like Lipitor deserve strong patent protection under our laws.".

Ruling shortens Pfizer's Lipitor patent by 15 months - Aug. 2, 2006

Pfizer's basic patent on its top-selling drug Lipitor was upheld in federal This means that Pfizer has patent protection on the cholesterol-cutting drug.

Ranbaxy scores in patent battle against Pfizer - Aug. 17, 2007

New York-based Pfizer still holds its basic Lipitor patent, which protects the world's top-selling drug until March 2010. Haskins said an initial rejection.